Risk of adverse cardiac events was low among patients who visited an emergency department for chest pain, tightness, burning or pressure with two negative troponin tests. The primary outcome -- life-threatening arrhythmia, inpatient STEMI, cardiac or respiratory arrest and death -- was experienced by 0.18% of patients. Among those who lacked abnormal vital signs and ischemic electrocardiographic findings, 0.06% of patients experienced an adverse event.
Two Phase III clinical studies showed that cardiac sympathetic nerve imaging using the AdreView radiopharmaceutical might help determine patients' risk of cardiac death and cardiac arrhythmias, said GE Healthcare, the maker of the radiopharmaceutical. The two trials make up the ADMIRE-HF trial, which was undertaken in 96 centers across Europe and North America.
A new study found the number of hospital stays for diabetes patients ages 0 to 29 years increased 38% from 1993 to 2004. Researchers said the increase in hospitalization rates was more significant for female diabetics than male diabetics.
"Fusion" workout options will become popular in 2008, and technology will enable more personalized workouts. Yoga, fitness campaigns, children's workouts, retro exercises and specialty fitness also are expected to be popular next year.
Bristol-Myers Squibb Co.'s cholesterol-lowering drug Pravachol reduced the risk of heart attack or death from heart disease for at least 10 years after male patients stopped taking the statin, researchers report. The study further supports previous data that confirms the long-term cardiac benefits of statins, which are commonly prescribed indefinitely, especially for people with heart disease.